Evaluation of the Effects of High Intensity Laser Therapy and Exercise in Hand Thumb Osteoarthritis
Launched by TC ERCIYES UNIVERSITY · Aug 1, 2025
Trial Information
Current as of September 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
First carpometacarpal (CMC) joint osteoarthritis (OA) is a common degenerative disease of the hand that causes severe pain, stiffness, weakness, and increased functional loss. It is based on joint degeneration involving articular surface deterioration, osteophyte formation, and ligamentous laxity. It is a prevalent condition in the aging population and can significantly affect hand function. The disease affects approximately 7% of men and 15% of women over the age of 50. First CMC joint OA can lead to pain and deformity at the base of the thumb, resulting in limitations in activities of dai...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with stage I, II, or III carpometacarpal joint osteoarthritis in their dominant hand based on radiographic findings according to the Eaton-Littler-Burton classification system
- • Patients experiencing pain equal to or greater than 4 on the Visual Analog Scale during activities of daily living
- • Patients who agree to complete the provided clinical evaluation scales to assess treatment efficacy and who can sign the informed consent form
- Exclusion Criteria:
- • Patients with a history of neurological diseases affecting the upper extremity
- • Patients with a history of rheumatological diseases
- • Patients who have received any treatment for hand problems (including intra-articular joint injections) within the last six months
- • Patients with severe hand and wrist injuries (such as fractures)
- • Patients with a surgical history related to the thumb
- • Patients diagnosed with hand or finger tenosynovitis, Dupuytren's disease, or Carpal Tunnel Syndrome
- • Patients with conditions contraindicating laser therapy (cardiac pacemaker, cancer, pregnancy, uncontrolled diabetes mellitus, uncontrolled hypertension)
About Tc Erciyes University
TC Erciyes University is a leading academic institution in Turkey, dedicated to advancing medical research and healthcare through innovative clinical trials. With a strong emphasis on scientific excellence and collaboration, the university leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies aimed at improving patient outcomes. Committed to ethical standards and regulatory compliance, TC Erciyes University fosters a research environment that promotes the development of new therapies and interventions, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kayseri, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported